Aditxt, Inc. Operating Lease Cost
Aditxt, Inc. (ADTX) reported Operating Lease Cost of $294.88 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-05-20
- Aditxt, Inc. operating lease, cost for the quarter ending 2026-03-31 was $294.88K, a 12.46% increase year-over-year.
- Aditxt, Inc. operating lease, cost for the quarter ending 2025-12-31 was $305.16K, a 106.48% increase year-over-year.
- Aditxt, Inc. operating lease, cost for the quarter ending 2025-09-30 was $297.30K, a 38.44% decline year-over-year.
- Aditxt, Inc. operating lease, cost for the quarter ending 2025-06-30 was $293.82K, a 1.41% decline year-over-year.
- Aditxt, Inc. operating lease, cost for fiscal 2025 was $1.16M, a 6.10% decline from fiscal 2024.
- Aditxt, Inc. operating lease, cost for fiscal 2024 was $1.23M, a 8.14% increase from fiscal 2023.
- Aditxt, Inc. operating lease, cost for fiscal 2023 was $1.14M.
- Aditxt, Inc. operating lease, cost for fiscal 2020 was $154.26K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-03-31 | $294.88K 10-Q · filed 2026-05-20 | $600.05K derived: sum of 2 quarters · filed 2026-05-20 | $897.35K derived: sum of 3 quarters · filed 2026-05-20 | $1.19M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-12-31 | $305.16K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $602.47K derived: sum of 2 quarters · filed 2026-03-31 | $896.29K derived: sum of 3 quarters · filed 2026-03-31 | $1.16M 10-K · filed 2026-03-31 |
| 2025-09-30 | $297.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | $591.12K derived: sum of 2 quarters · filed 2025-11-18 | $853.33K 10-Q · filed 2025-11-18 | $1.00M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | $293.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $556.03K 10-Q · filed 2025-08-14 | $703.82K derived: sum of 3 quarters · filed 2026-05-20 | $1.19M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | $262.21K 10-Q · filed 2026-05-20 | $410.00K derived: sum of 2 quarters · filed 2026-05-20 | $892.91K derived: sum of 3 quarters · filed 2026-05-20 | $1.19M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $147.79K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $630.71K derived: sum of 2 quarters · filed 2026-03-31 | $928.73K derived: sum of 3 quarters · filed 2026-03-31 | $1.23M 10-K · filed 2026-03-31 |
| 2024-09-30 | $482.91K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-18 | $780.94K derived: sum of 2 quarters · filed 2025-11-18 | $1.09M 10-Q · filed 2025-11-18 | $1.26M derived: sum of 4 quarters · filed 2025-11-18 |
| 2024-06-30 | $298.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $603.07K 10-Q · filed 2025-08-14 | $780.81K derived: sum of 3 quarters · filed 2025-08-14 | $1.15M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $305.05K 10-Q · filed 2025-05-15 | $482.79K derived: sum of 2 quarters · filed 2025-05-15 | $849.44K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $177.74K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $544.39K derived: sum of 2 quarters · filed 2025-03-31 | $1.14M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $366.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $963.21K 10-Q · filed 2024-11-18 | ||
| 2023-06-30 | $596.56K 10-Q · filed 2024-08-19 | |||
| 2020-12-31 | $107.56K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $154.26K 10-K · filed 2021-03-25 | ||
| 2020-09-30 | $46.70K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |